共 92 条
[1]
Siegel R.L., Miller K.D., Fuchs H.E., Jemal A., Cancer statistic, CA Cancer J Clin, 72, pp. 7-33, (2022)
[2]
De Leo A., Santini D., Ceccarelli C., Santandrea G., Palicelli A., Acquaviva G., Et al., What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors, Diagnostics (Basel), 11, (2021)
[3]
Prat J., Ovarian, fallopian tube and peritoneal cancer staging: rationale and explanation of new figo staging 2013, Best Pract Res Clin Obstet Gynaecol, 29, (2015)
[4]
Baci D., Bosi A., Gallazzi M., Rizzi M., Noonan D.M., Poggi A., Et al., The ovarian cancer tumor immune microenvironment (Time) as target for therapy: A focus on innate immunity cells as therapeutic effectors, Int J Mol Sci, 21, (2020)
[5]
Chardin L., Leary A., Immunotherapy in ovarian cancer: thinking beyond pd-1/pd-L1, Front Oncol, 11, (2021)
[6]
Lai P., Rabinowich H., Crowley-Nowick P.A., Bell M.C., Mantovani G., Whiteside T.L., Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma, Clin Cancer Res, 2, (1996)
[7]
Bernson E., Huhn O., Karlsson V., Hawkes D., Lycke M., Cazzetta V., Et al., Identification of tissue-resident natural killer and T lymphocytes with anti-tumor properties in ascites of ovarian cancer patients, Cancers (Basel), 15, (2023)
[8]
Kim S., Kim B., Song Y.S., Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer, Cancer Sci, 107, (2016)
[9]
Wefers C., Lambert L.J., Torensma R., Hato S.V., Cellular immunotherapy in ovarian cancer: targeting the stem of recurrence, Gynecol Oncol, 137, (2015)
[10]
Fan S., Gao X., Qin Q., Li H., Yuan Z., Zhao S., Association between tumor mutation burden and immune infiltration in ovarian cancer, Int Immunopharmacol, 89, (2020)